marked.bio

Company

Ranok Therapeutics

2 active trials that select patients by a biomarker on marked.bio, across 1 biomarker.

Counts only trials this company leads as sponsor, not partnered or academic trials of its drugs.

Biomarkers

Upcoming readouts

Active phase 2 and 3 trials whose primary completion date falls in the next 12 months, according to the sponsor.

Trials

2 of 2 trials shown

  1. To Evaluate the Safety and Efficacy of RNK08954 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma.

    Recruiting Phase 2 Ranok Therapeutics Started 2025Primary completion 2026-11 NCT07303465

    RNK08954

    Presence of a KRAS G12D mutation.

    KRAS G12DKRAS G12D Mutations, Pancreatic Ductal Adenocarcinoma (PDAC)

  2. A Study of RNK08954 in Subjects With Advanced Solid Tumors With KRAS ((Kirsten Rat Sarcoma) G12D Mutation

    Recruiting Phase 1/2 Ranok Therapeutics Started 2024Primary completion 2026-12 NCT06667544

    RNK08954-01

    Must have pathologically documented locally advanced or metastatic malignancy harboring KRAS G12D mutations identified through deoxyribonucleic acid (DNA) sequencing of tumor tissues or c…

    KRAS G12DKRAS G12D Mutation